<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151706</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-49023</org_study_id>
    <secondary_id>BMT339</secondary_id>
    <secondary_id>IRB-49023</secondary_id>
    <nct_id>NCT04151706</nct_id>
  </id_info>
  <brief_title>CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS&amp;AL</brief_title>
  <official_title>CD34 Selected Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning and CD8+ Memory T Cell Infusion For Patients With Myelodysplastic Syndrome and Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate combining stem cells from the patient's matched sibling donor (a
      standard CD34-selected transplant) with a second infusion of white blood cells called &quot;CD8
      memory T-cells&quot; from their sibling donor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To determine the rate of graft versus host disease (GvHD) free, relapse
      free survival (GRFS) at one year following CD34 selected allogeneic hematopoietic cell
      transplantation using myeloablative conditioning combined with an infusion of phenotypic CD8+
      memory T cells from human leukocyte antigen (HLA) matched donors for patients with
      myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or acute lymphoblastic leukemia
      (ALL).

      Secondary Objective: To determine the rate of graft rejection, acute and chronic GvHD, non
      relapse mortality, relapse, overall survival, and disease free survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft versus Host Disease (GvHD) free and relapse free survival (GRFS)</measure>
    <time_frame>1 year</time_frame>
    <description>The rate of participants who do not experience GvHD and also do not experience relapse are collectively considered to be GRFS. Relapse will be assessed according to the myelodysplastic syndrome or leukemia response criteria. The participants will be assessed for GRFS though 1 year post transplant. The outcome will be reported as the number of participants, a number without dispersion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft Rejection</measure>
    <time_frame>1 year</time_frame>
    <description>Graft rejection will be determined on the basis of reaction against the donor hematopoietic cells. The outcome will be reported as the number of participants who experience graft rejection though 1 year post transplant, a number without dispersion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft versus Host Disease (GvHD)</measure>
    <time_frame>1 year</time_frame>
    <description>The participants will be assessed for acute graft versus host disease (GvHD) though 1 year post transplant. The outcome will be reported as the number of participants who experience acute GvHD, a number without dispersion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft versus Host Disease (GvHD)</measure>
    <time_frame>1 year</time_frame>
    <description>The participants will be assessed for chronic, steroid requiring graft versus host disease (GvHD) though 1 year post transplant. The outcome will be reported as the number of participants who experience chronic GvHD, a number without dispersion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non relapse Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>: Non relapse mortality will be assessed as the number of participants who have died though 1 year post transplant, without a relapse or recurrence of their myelodysplastic syndrome or leukemia. Relapse will be assessed according to the myelodysplastic syndrome or leukemia response criteria. The outcome will be reported as the number of affected participants, a number without dispersion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>1 year</time_frame>
    <description>Relapse will be assessed according to the myelodysplastic syndrome or leukemia response criteria. The outcome will be reported as the number of participants who experience relapse though 1 year post transplant, a number without dispersion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>Overall Survival (OS) will be assessed as the number of participants who remain alive at 1 year post transplant. The outcome will be reported as a number without dispersion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>fTBI/Thiotepa/fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be infused on Day 0 with CD34+ selected cells and CD8+CD45RA T cells following a standard non anti-thymocyte globulin (ATG) containing regimen used for CD34 selected transplants consisting of fractionated total body irradiation (fTBI) (1375 cGy); thiotepa (10 mg/kg); and fludarabine (125 mg/m2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD8+ Memory T Cell Selection</intervention_name>
    <description>Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation</description>
    <arm_group_label>fTBI/Thiotepa/fludarabine</arm_group_label>
    <other_name>Enriched for CD8+CD45RA memory T cells.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thio Tepa</intervention_name>
    <description>5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)</description>
    <arm_group_label>fTBI/Thiotepa/fludarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)</description>
    <arm_group_label>fTBI/Thiotepa/fludarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hyperfractionated TBI</intervention_name>
    <description>Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)</description>
    <arm_group_label>fTBI/Thiotepa/fludarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion Criteria:

          -  Acute leukemia, in morphologic complete remission, OR myelodysplasia with &lt; 10% blasts
             in the marrow, and no circulating blasts that contain auer rods. Patients with chronic
             myelomonocytic leukemia (CMML) must have a WBC count ≤ 10,000 cells/μL and &lt; 10%
             blasts in the marrow.

          -  Planned myeloablative conditioning regimen at Stanford University Medical Center.

          -  Karnofsky or Lansky Performance Score ≥ 70%.

          -  Must have an HLA related donor as follows: onor must be an 8/8 match for HLA A, B and
             C at intermediate (or higher) resolution, and DRB1 at high resolution using DNA based
             typing. The donors must be willing to receive G CSF followed by collection of cells by
             apheresis, and must meet the Program's criteria for donation.

          -  Cardiac function: Ejection fraction at rest ≥ 40%.

          -  Serum creatinine value of &lt; 1.5 mg/dL, or an estimated creatinine clearance greater
             than 50 mL/minute (using the Stanford calculator for eGFR available in EPIC)

          -  Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 50% (adjusted for Hgb)

          -  Forced vital capacity (FVC) ≥ 50%.

          -  Forced expiratory volume (FEV1) ≥ 50%.

          -  Total bilirubin &lt; 2 times the upper limit of normal (ULN) (unless the elevated
             bilirubin is attributed to Gilbert's Syndrome)

          -  Alanine aminotransferase (ALT) &lt; 2.5 x ULN

          -  Aspartate aminotransferase (AST) &lt; 2.5 x ULN

          -  Total bilirubin &lt; 2 times the upper limit of normal (unless elevated bilirubin is
             attributed to Gilbert's Syndrome)

          -  Signed informed consent

        Recipient Exclusion Criteria:

          -  Prior autologous or allogeneic hematopoietic stem cell transplant

          -  Prior malignancies, except resected non melanoma or treated cervical carcinoma in
             situ. Cancer treated with curative intent ≥ 5 years previously is allowed. Cancer
             treated with curative intent &lt; 5 years previously will not be allowed unless approved
             by the Protocol Officer or one of the Protocol Chairs

          -  Active central nervous system (CNS) involvement by malignant cells

          -  Presence of fluid collection (ascites, pleural or pericardial effusion) that
             interferes with methotrexate clearance or makes methotrexate use contraindicated

          -  Requirement for supplemental oxygen

          -  Uncontrolled bacterial, viral or fungal infections (currently taking medication and
             with progression or no clinical improvement) at time of enrollment

          -  History of uncontrolled autoimmune disease or on active treatment (defined as &gt; 5 mg
             prednisone daily)

          -  Seropositive for HIV 1 or 2

          -  Seropositive for HTLV I or -II

          -  Active Hepatitis B or C viral replication by polymerase chain reaction (PCR)

          -  Documented allergy to iron dextran or murine proteins

          -  Pregnant (positive serum or urine βHCG) or breastfeeding)

          -  Females of childbearing potential (FCBP) or men who have sexual contact with FCBP
             unwilling to use an effective form of birth control or abstinence for one year after
             transplantation

          -  Unable to comply with the treatment protocol, including appropriate supportive care,
             follow up and research tests.

          -  Planned to receive post transplant maintenance therapy except for fms-like tyrosine
             kinase 3 (FLT3) inhibitors or BCR ABL tyrosine kinase inhibitors (TKIs).

        Donor Inclusion Criteria:

          -  HLA matched donor (matching at 8/8 antigens or alleles including HLA A, B, C, and
             -DRB1).

          -  ≥ 18 years to &lt; 66.0 years

          -  State of general good health

          -  Completed a donor evaluation with history, medical examination and standard blood
             tests within 60 days of starting the hematopoietic cell collection procedure. In order
             to fairly represent the interests of the donor, the donor evaluation and consent will
             be performed by a study team member other than the recipient's attending physician.

          -  Hepatitis A, B and C, HIV 1 and 2, HTLV, VZV, EBV, HSV, West Nile virus, Syphilis
             Treponema, T cruzi (Chagas), CMV, and the MPX NAT IDT (HIV/HCV/HBV) will be tested as
             per national standard of care guidelines for transplant donors. Donors who are HIV
             positive will be excluded. Donors who are positive by serology for Hepatitis B or C
             are eligible as long as PCR for RNA/DNA is negative

          -  White blood cell count &gt; 3.5 x 109/L

          -  Platelets &gt; 150 x 109/L

          -  Hematocrit &gt; 35%

          -  Capable of undergoing leukapheresis

          -  Able to understand and sign informed consent

        Donor Exclusion Criteria:

          -  Psychological traits or psychological or medical conditions which make them unlikely
             to tolerate the procedure

          -  Pregnant or lactating female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lowsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Gaudinez</last_name>
    <phone>650-725-4983</phone>
    <email>mgaudinez@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

